ft 27 sep 93 uk compani news detail first rival zovirax reveal detail first competitor zovirax best sell product wellcom uk pharmaceut group reveal yesterday smithklin beecham anglo american healthcar group present clinic data show new drug famciclovir safe effect zovirax requir less frequent dose zovirax anti herp treatment also use shingl worldwid sale last financi year pound 586m make world eighth best sell medicin broker morgan stanley expect sale reach pound 1 3bn 1997 drug repres 34 per cent wellcom sale competitor 12 year sinc launch difficulti develop non toxic anti herp remedi although smithklin beecham drug effect zovirax data signific anglo american group recent aggress price strategi group world lead antibiot compani also far larger salesforc wellcom particularli us wellcom develop successor zovirax call valaciclovir present data new orlean next month show drug effect zovirax requir less frequent dose smithklin beecham expect file dossier regulatori author first shingl repres third half zovirax sale compani also plan file genit herp includ primari attack recurr episod mainten treatment prevent herp outbreak also hope develop product treat cold sore later date dossier shingl given us food drug administr june given 18 countri first trial present european academi dermato venereolog copenhagen compar famciclovir zovirax shingl patient demonstr smithklin beecham drug effect wellcom famciclovir test 798 patient dose 750mg 500mg 250mg three time day zovirax 800mg five time day present recommend regimen shingl patient trial show famciclovir three dose effect zovirax mark benefit wellcom drug second trial design test safeti drug compar famciclovir placebo 419 patient trial show statist differ side effect patient drug placebo result come relief smithklin beecham mani drug class zovirax famciclovir drop toxic zovirax also soon face competit japanes drug sorivudin develop nippon shoji kaisha